title: Omission of lymphadenectomy is possible for low-risk corpus cancer.
abstract: OBJECTIVE
  The objective of this study is to ascertain whether omission of lymphadenectomy is possible when endometrial cancer is considered low-risk based on intraoperative pathologic indicators.
  
  
  METHODS
  A total of 128 patients were deemed to be low-risk based on intraoperative evaluation, including frozen-section determination of grade and myometrial invasion. We divided these 128 patients into 2 groups, the total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH-BSO) with lymphadenectomy (LA group, n=68) and the TAH-BSO without lymphadenectomy (non-LA group, n=60) group. The only adjuvant treatment used was chemotherapy, and the decision to use chemotherapy was based on stage, grade, or lymphovascular space involvement. A retrospective review of the medical records was performed, and disease-free survival (DFS), overall survival (OS), operative time, estimated blood loss during operation, percentage of transfusion requirement, incidence of post-operative leg lymphedema and post-operative deep vein thrombosis were evaluated.
  
  
  RESULTS
  The 5-year DFS and OS rates were 95.6% and 98.5% in the LA group, and 98.3% and 98.3% in the non-LA group, respectively, and were not significantly different. In the LA group, pelvic lymph node metastasis was observed in only 1 case. In the LA group, blood loss during operation, percentage of transfusion requirement and the incidence of post-operative leg lymphedema were significantly higher than those in the non-LA group.
  
  
  CONCLUSIONS
  Lymphadenectomy did not provide a significant survival advantage in the patients with low-risk corpus cancer. Additionally, some peri- and post-operative morbidities and complications were increased by the addition of lymphadenectomy. The present findings suggest that lymphadenectomy should be limited for low-risk corpus cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Toyama, 2630, Sugitani, Toyama-shi, Toyama 930-0194, Japan. hidaka@med.u-toyama.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Hidaka
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: R
authors.initials: R
authors.lastname: Yonezawa
authors.forename: T
authors.initials: T
authors.lastname: Shima
authors.forename: A
authors.initials: A
authors.lastname: Nakashima
authors.forename: K
authors.initials: K
authors.lastname: Nagira
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: S
authors.initials: S
authors.lastname: Saito
mesh_terms: D000328:Adult; D000368:Aged; D018269:Carcinoma, Endometrioid / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D000075202:Contraindications; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate